Recruiting
Phase 2

WAL0921

Sponsor:

Walden Biosciences

Code:

NCT06466135

Conditions

Diabetic Nephropathies

Primary Focal Segmental Glomerulosclerosis

Minimal Change Disease

Primary Immunoglobulin A Nephropathy

Primary Membranous Nephropathy

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

WAL0921

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-06-28. This information was provided to ClinicalTrials.gov by Walden Biosciences on 2026-04-02.